This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dawson, G J Articles by Devare, S G Search for Related Content PubMed PubMed Citation Articles by Dawson, G J Articles by Devare, S G

Detection of antibodies to hepatitis C virus in U.S. blood donors.

Abbott Diagnostics Division, Abbott Laboratories, North Chicago, Illinois 60064.

ABSTRACT

An enzyme immunoassay (EIA) which utilizes a solid phase coated with a recombinant antigen (c100-3) derived from the hepatitis C virus (HCV) genome was evaluated for efficacy in the detection of antibodies to HCV (anti-HCV). The sensitivity of the antibody test was demonstrated by the detection of anti-HCV in a well-characterized panel of human specimens known to contain the infectious agent of non-A, non-B hepatitis. The specificity of the anti-HCV test was evaluated by testing 6,118 serum specimens from volunteer blood donors considered to be at low risk for exposure to HCV. The specificity of the anti-HCV EIA was demonstrated to be 99.56%, since 6,069 of 6,096 specimens from this low-risk group were nonreactive. A total of 49 (0.80%) of the 6,118 specimens were repeatedly reactive in the test, and 22 (46.81%) of the 47 specimens available for additional testing were confirmed as positive for antibodies to HCV c100-3. Among commercial plasma donors, 390 (10.49%) of 3,718 specimens were repeatedly reactive in the EIA. A total of 375 (97.40%) of the 385 specimens available for further testing were confirmed as positive. These limited data indicate that the prevalence of antibodies to HCV is 0.36% (22 confirmed positives among 6,118 specimens) among volunteer blood donors and 10.08% (375 confirmed positives among 3,718 specimens) among commercial plasma donors. The importance of confirmatory testing is discussed.

This article has been cited by other articles:

• UNGO, J. R., JONES, D., ASHKIN, D., HOLLENDER, E. S., BERNSTEIN, D., ALBANESE, A. P., PITCHENIK, A. E. (1998). Antituberculosis Drug-induced Hepatotoxicity . The Role of Hepatitis C Virus and the Human Immunodeficiency Virus. Am. J. Respir. Crit. Care Med. 157: 1871-1876 [Abstract] [Full Text]  
• SHAPIRO, C. N., TOKARS, J. I., CHAMBERLAND, M. E. (1996). Use of the Hepatitis-B Vaccine and Infection with Hepatitis B and C among Orthopaedic Surgeons. JBJS 78: 1791-1800 [Abstract] [Full Text]